2018 Innovative Korean & POWER KOREA Grand Prize - Focusing on the development of cranial nerve protection and treatment for autism and ADHD.

Neuroventi Co., Ltd. (CEO Shin Chan-young), a venture company specializing in biopharmaceutical research, has taken on the challenge of developing treatments for autism spectrum disorder (autism) and attention deficit hyperactivity syndrome (ADHD).

CEO Shin Chan-young, a professor at Konkuk University Medical School, established the company in 2015 to pay attention to autism, the only mental disorder for which there is no definite treatment yet, and to develop a specialized treatment. The research team of Neuroventi Co., Ltd. focused on developing a treatment that inhibits iGluR, an ion channel type glutamic acid receptor, securing technical rights for iGluR inhibitor candidates at home and abroad and conducting mechanism research.

In addition, through various autism animal models, sociality and social selectivity of autism animals were measured to establish a system that can search for autism spectrum disorder treatments, and studies were conducted to evaluate the efficacy of multi-action point treatment for autism. As a result, it was confirmed that iGluR inhibitors improve social deficits, repetitive and hyperactive behaviors, which are core symptoms of autism, effectively control accompanying symptoms such as seizures, and improve social deficits by controlling brain excitability.

In addition, 20-25% of ADHD patients do not respond to stimulant-type drugs, and safety issues are emerging due to various side effects. As a mechanism, we are developing a substance that can treat three core symptoms without three side effects.

Neuroventi Co., Ltd., which was selected as the sixth investment company related to bio-specialized investment in the 'TIPS' program of the Ministry of SMEs and Startups, is committed to research with the goal of clinical entry of a new drug candidate for autism in 2021. In addition, in order to commercialize autism treatment, we are establishing a commercialization strategy to transfer technology to overseas partners, partners, investors, and domestic and foreign companies.

CEO Shin expressed his ambition, saying, "We will develop personalized medicines, health functional foods, and functional cosmetics that meet the era of the 4th industrial revolution and leap forward as a global bio-healthcare company."